On February 1st 2019, the FDA announced its approval of a new alternative to Allergan’s Botox, known as Jeuveau. Marketed by Evolus, a medical aesthetics company, Jeuveau is the first product expected to challenge Botox in the improvement of prominent facial moderate to severe frown lines, commonly referred to as expression lines, in both men and women.
Launched in 2002, Botox’s popularity has steadily increased, ranking it amongst the top non-surgical aesthetic treatments. In addition, Botox quickly advanced into the medical field by providing relief and treatment for chronic migraines and eyelid spasms. However, Jeuveau is the first FDA-approved neurotoxin dedicated solely for aesthetics . In this sense, the producers of Jeuveau set their primary concerns for aesthetic consumers.
As stated by the President and CEO of Evolus, David Moatazedi, “What makes Evolus unique is our focus on delivering performance beauty products with a customer-centric approach. We are pleased to introduce Jeuveau, the first FDA approved neurotoxin dedicated to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology.”
In addition, Jeuveau is reported to have shown clinically better results during its phase III study, compared to Botox. As providers learn more, they are eager to offer their patients Evolus’ new leading product. Ava Shamban MD, Board Certified Dermatologist and clinical investigator noted, “The outcomes I’ve seen for my clinical trial patients firsthand, combined with the comprehensive clinical data set for Jeuveau provide a compelling new treatment option for physicians and their aesthetic patients. Importantly, there were no serious drug related adverse events reported. I look forward to incorporating Jeuveau™ into my aesthetic product offering.”
Patients can expect to see Jeuveau offered at physician offices starting Spring of 2019.